Skip to main content
SpringerLink
Log in

Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types

Pharmacological Properties and Clinical Evaluation

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Satraplatin is the first orally administered platinum drug to be evaluated in the clinic. Oral satraplatin plus prednisone improved progression free survival significantly relative to prednisone alone in patients with hormone-refractory prostate cancer in a randomised study. Furthermore, single-agent satraplatin has demonstrated activity in ovarian cancer and small cell lung cancer similar to that observed with single-agent cisplatin or carboplatin. In >600 treated patients, satraplatin was generally well tolerated and the most common adverse event was non-cumulative myelosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III

Similar content being viewed by others

References

  1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005 Apr; 4 (4): 307–20

    Article  PubMed  CAS  Google Scholar 

  2. Hartwig JF, Lippard SJ. DNA binding properties of cis-[Pt(NH3)(C6H11NH2)Cl2], a metabolite of an orally active platinum anticancer drug. J Am Chem Soc 1992 Jul; 114 (14): 5646–54

    Article  CAS  Google Scholar 

  3. Vaisman A, Lim S, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity of translesion synthesis past platinum-DNA adducts. Biochemistry 1999 Aug; 38 (34): 11026–39

    Article  PubMed  CAS  Google Scholar 

  4. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996 Nov; 56 (21): 4881–6

    PubMed  CAS  Google Scholar 

  5. Wei M, Cohen SM, Silverman AP, et al. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 2001 Oct; 276 (42); 38774–80

    Article  PubMed  CAS  Google Scholar 

  6. Twentyman PR, Wright KA, Mistry P, et al. Sensitivity to novel platinum compounds of panels of human lung-cancer cell-lines with acquired and inherent resistance to cisplatin. 1992 Oct; 52 (20): 5674–80

    CAS  Google Scholar 

  7. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993 Jun;53 (11): 2581–6

    PubMed  CAS  Google Scholar 

  8. Wosikowski K, Caligiuri M, Lamphere L, et al. Efficacy of satraplatin, an oral platinum analogue in prostate cancer: synergistic activity with docetaxel [abstract no. 351]. ASCO Prostate Cancer Symposium; 2006 Feb 24–26; San Francisco (CA)

  9. Mellish KJ, Kelland LR, Harrap KR. In-vitro platinum drug chemosensitivity of human cervical squamous-cell carcinoma cell-lines with intrinsic and acquired-resistance to cisplatin. Br J Cancer 1993 Aug; 68 (2): 240–50

    Article  PubMed  CAS  Google Scholar 

  10. McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally-administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in-vivo. Cancer Res 1994 Aug; 54 (15): 4118–22

    PubMed  CAS  Google Scholar 

  11. Wosikowski K. Efficacy of satraplatin (JM-216) and its metabolites is maintained in taxane-resistant tumors. 1st Conference on Cancer Therapeutics-Molecular Targets, Pharmacology and Clinical Applications, International Chemotherapy Society; 2004 Feb 19–21; Florence

  12. Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997 May; 40 (1): 51–6

    Article  PubMed  CAS  Google Scholar 

  13. Amorino GP, Mohr PJ, Hercules SK, et al. Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 2000 Nov; 46 (5): 423–6

    Article  PubMed  CAS  Google Scholar 

  14. Lamphere L, Obermayr F, Caligiuri M, et al. Satraplatin, an oral platinum analogue, is active and synergistic with paclitaxel and docetaxel in prostate cancer models [abstract no. 14620]. ASCO Annual Meeting; 2006 Jun 2–6; Atlanta (GA)

  15. McKeage MJ, Mistry P, Ward J, et al. A phase-I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995 Oct; 36 (6): 451–8

    Article  PubMed  CAS  Google Scholar 

  16. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998 Jul; 42 (2): 142–8

    Article  PubMed  CAS  Google Scholar 

  17. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997 Jul; 15 (7): 2691–700

    PubMed  CAS  Google Scholar 

  18. Kurata T, Tamura T, Sasaki Y, et al. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 2000 Sep; 30 (9): 377–84

    Article  PubMed  CAS  Google Scholar 

  19. Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998 Dec; 9 (12): 1315–22

    Article  PubMed  CAS  Google Scholar 

  20. Carr JL, Tingle MD, McKeage MJ. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 2002 Jul; 50 (1): 9–15

    Article  PubMed  CAS  Google Scholar 

  21. Raynaud FI, Mistry P, Donaghue A, et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996 Jun; 38 (2): 155–62

    Article  PubMed  CAS  Google Scholar 

  22. Poon GK, Mistry P, Raynaud FI, et al. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J Pharm Biomed Anal 1995 Nov; 13 (12): 1493–8

    Article  PubMed  CAS  Google Scholar 

  23. Galettis P, Carr JL, Paxton JW, et al. Quantitative determination of platinum complexes in human plasma generated from the oral antitumour drug JM216 using directly coupled high-performance liquid chromatography-inductively coupled plasma mass spectrometry without desolvation. J Anal Atom Spectrom 1999 Jun; 14 (6): 953–6

    Article  CAS  Google Scholar 

  24. Berners-Price SJ, Appleton TG. The chemistry of cisplatin in aqueous solution. In: Kelland LR, Farrell NP, editors. Platinum-based drugs in cancer therapy. Totowa (NJ): Humana Press, 2000: 3–36

    Chapter  Google Scholar 

  25. Carr JL, Tingle MD, McKeage MJ. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother Pharmacol 2006 Apr; 57 (4): 483–90

    Article  PubMed  CAS  Google Scholar 

  26. Jones S, Hainsworth J, Burris HA, et al. Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002 Feb; 20 (1): 55–61

    Article  PubMed  CAS  Google Scholar 

  27. DeMario MD, Ratain MJ, Vogelzang NJ, et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999 May; 43 (5): 385–8

    Article  PubMed  CAS  Google Scholar 

  28. George CM, Haraf DJ, Mauer AM, et al. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 2001; 19: 10

    Article  Google Scholar 

  29. Cmelak A, Choy H, Murphy B, et al. Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer [abstract no. 1520]. ASCO Annual Meeting; 1999 May 15–18; Atlanta (GA)

  30. American Cancer Society. Cancer facts and figures 2005 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf [Accessed 2007 Mar 16]

  31. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer Suppl 1993; 71 (3): 1098–109

    CAS  Google Scholar 

  32. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 Oct; 351 (15): 1513–20

    Article  PubMed  CAS  Google Scholar 

  33. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct; 351 (15): 1502–12

    Article  PubMed  CAS  Google Scholar 

  34. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68 (1): 2–9

    CAS  Google Scholar 

  35. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (acetato) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drug 2005 Jan; 23 (1): 79–84

    Article  CAS  Google Scholar 

  36. Fokkema E, Groen HJM, Bauer J, et al. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell long cancer. J Clin Oncol 1999 Dec; 17 (12): 3822–7

    PubMed  CAS  Google Scholar 

  37. Fokkema E, Lunenberg J, Putten JWG, et al. Randomized phase II study of oral JM216 versus intravenous (iv) cisplatin in non-small cell lung cancer (NSCLC): preliminary results [abstract no. 1858]. ASCO Annual Meeting; 1998 May 16–19; Los Angeles (CA)

  38. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997 Jun; 8 (6): 604–6

    Article  PubMed  CAS  Google Scholar 

  39. Trudeau M, Stuart G, Hirte H, et al. A phase II trial of JM-216 in cervical cancer: An NCICCTG study. Gynecol Oncol 2002 Feb; 84 (2): 327–31

    Article  PubMed  CAS  Google Scholar 

  40. Anonymous. A randomized phase II study of satraplatin (JM-216) or standard platinum therapy in patients with late relapses of epithelial ovarian cancer (CA 142-006). Bristol-Myers Squibb Report; 1998 Jun 9. Accession No. 910068667

  41. Petrylak DP, Sartor O, Witjes F, et al. A phase III, randomized, doubled-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC) [abstract no. 145]. ASCO Prostate Cancer Symposium; 2007 Feb 22–24; Orlando (FL)

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr McKeage has acted as a consultant for, and the University of Auckland has received research grants from, GPC Biotech.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine & Health Science, University of Auckland, Private Bag 92019, Auckland, New Zealand

    Mark J. McKeage

Authors
  1. Mark J. McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark J. McKeage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McKeage, M.J. Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types. Drugs 67, 859–869 (2007). https://doi.org/10.2165/00003495-200767060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767060-00003

Keywords

Search

Navigation